Regorafenib alleviates tumor growth, angiogenesis, and metastasis by inactivating angiogenic and oncogenic kinases, such as the vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) receptor, Raf, and mast/stem cell growth factor receptor (c-KIT) [3,4]. Here, VEGFA is linked to neoplasm.